Bottom line
What is LHCAX's expense ratio?
LHCAX's expense ratio is 1.03%, or about $103 a year on every $10,000 invested. That is more expensive than 53% of health care sector funds we track (median 0.96%). This share class also charges a front-end sales load of up to 5.75%, taken from your investment when you buy. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Feb 25, 2026
LHCAX fee table
| Net expense ratio | 1.03% |
|---|---|
| Gross expense ratio | 3.48% |
| Management fee | 0.62% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 2.61% |
| Fee waiver / reimbursement | -2.45% |
| Max front-end sales load | 5.75% |
| Max deferred sales charge | 0% |
Source: Fund prospectus fee table, filed Feb 25, 2026
What LHCAX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| LHCAX | $674 | $1,366 | $2,080 | $3,961 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.03% expense ratio costs roughly $56,900 in lost growth, versus about $53,400 for the median health care sector fund (0.96%).